ProfileGDS5678 / 1435001_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 71% 72% 76% 73% 71% 70% 72% 71% 71% 74% 71% 69% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5641572
GSM967853U87-EV human glioblastoma xenograft - Control 24.5313671
GSM967854U87-EV human glioblastoma xenograft - Control 34.5459872
GSM967855U87-EV human glioblastoma xenograft - Control 45.2640676
GSM967856U87-EV human glioblastoma xenograft - Control 54.7604673
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4335271
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4070670
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5209772
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5137871
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5153871
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8318874
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5179371
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.300169
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8328274